Search Clinical Trials
Sponsor Condition of Interest |
---|
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents...
Celgene
Lymphoma, Non-Hodgkin
The purpose of this study is to evaluate the safety, tolerability, and preliminary
efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants
with relapsed or refractory non-Hodgkin's lymphomas. expand
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas. Type: Interventional Start Date: May 2019 |
Blue Light Cystoscopy With Cysview® Registry
Photocure
Bladder Cancer
Registry study to gather more information on the current use of Blue Light Cystoscopy
with Cysview (BLCC) in urologists' practices. expand
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices. Type: Observational [Patient Registry] Start Date: Apr 2014 |
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants with Myotonic Dystrophy Type 1
PepGen Inc
Myotonic Dystrophy 1
The primary purpose of the study is to evaluate the safety and tolerability of single
intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy
Type 1 (DM1).
The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and
Observation Period... expand
The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and Observation Period (16 weeks). Type: Interventional Start Date: Dec 2023 |
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who...
SWOG Cancer Research Network
AL Amyloidosis
This phase III trial compares the effect of adding a stem cell transplant with melphalan
after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and
dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients
with newly diagnosed amyloid light chain... expand
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. The stem cells are then returned to the patients to replace the blood forming cells that were destroyed by the chemotherapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs, such as cyclophosphamide and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to lower the body's immune response to help stop the growth of cancer cells. Giving a stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in patients with newly diagnosed AL amyloidosis. Type: Interventional Start Date: Jul 2024 |
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated...
Novartis Pharmaceuticals
Coronary Artery Disease
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran,
in comparison to placebo taken in addition to statin medication can effectively reduce
the total amount of plaque formed in the heart's vessels as measured by coronary computed
tomography angiography (CCTA) from... expand
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's vessels as measured by coronary computed tomography angiography (CCTA) from baseline to month 24. This study is being conducted in eligible participants with a diagnosis of non-obstructive coronary artery disease (NOCAD), where the coronary arteries are blocked less than 50%, and with no previous cardiovascular events. Type: Interventional Start Date: Jul 2022 |
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib
works to shrink tumors in patients with solid tumors that are unlikely to be cured or
controlled with treatment and that may have spread from where it first started to nearby
tissue, lymph nodes, or distant parts... expand
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to completely repair damaged DNA. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Other genes are also involved in this process, and these are called DNA damage repair genes. The KRAS mutation is a change in a protein in normal cells. Normally KRAS serves as an information hub for signals in the cell that lead to cell growth, but when there is a mutation in KRAS it signals too much and cells grow without being told to, which causes cancer. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer. Type: Interventional Start Date: Nov 2022 |
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma
Primary CNS Lymphoma
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib
monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in
combination with one of two different high dose methotrexate based regimens
(methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/
vincristine)... expand
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B) Type: Interventional Start Date: Dec 2021 |
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy...
National Cancer Institute (NCI)
Diffuse Astrocytoma, IDH-Wildtype
Recurrent Glioblastoma
This phase II trial studies the best dose and effect of tocilizumab in combination with
atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose
tumor has come back after initial treatment (recurrent). Tocilizumab is a monoclonal
antibody that binds to receptors for... expand
This phase II trial studies the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose tumor has come back after initial treatment (recurrent). Tocilizumab is a monoclonal antibody that binds to receptors for a protein called interleukin-6 (IL-6), which is made by white blood cells and other cells in the body as well as certain types of cancer. This may help lower the body's immune response and reduce inflammation. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Fractionated stereotactic radiation therapy uses special equipment to precisely deliver multiple, smaller doses of radiation spread over several treatment sessions to the tumor. The goal of this study is to change a tumor that is unresponsive to cancer therapy into a more responsive one. Therapy with fractionated stereotactic radiotherapy in combination with tocilizumab may suppress the inhibitory effect of immune cells surrounding the tumor and consequently allow an immunotherapy treatment by atezolizumab to activate the immune response against the tumor. Combination therapy with tocilizumab, atezolizumab and fractionated stereotactic radiation therapy may shrink or stabilize the cancer better than radiation therapy alone in patients with recurrent glioblastoma. Type: Interventional Start Date: Mar 2022 |
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
GT Medical Technologies, Inc.
Brain Metastases
This trial will be a randomized controlled study comparing the efficacy and safety of
intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following
metastatic tumor resection which is the current standard of care. expand
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care. Type: Interventional Start Date: Apr 2021 |
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Seagen Inc.
Myelodysplastic Syndrome
Acute Myeloid Leukemia
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out
if it is safe for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia
(AML). It will study SEA-CD70 to find out what its side effects are and if it works for
AML and MDS. A side effect is anything... expand
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have six groups or "parts." - Part A will find out how much SEA-CD70 should be given to patients. - Part B will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat patients with MDS. - Part C will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat patients with AML. - Part D will find out how much SEA-CD70 with azacitidine should be given to patients. - Part E will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat patients with MDS or MDS/AML that has not been treated. - Part F will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat patients with MDS or MDS/AML. Type: Interventional Start Date: Aug 2020 |
ProACT Post-Approval Study
Uromedica
Stress Urinary Incontinence
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study
designed to evaluate the long-term incidence of urethral stricture and device erosion
after ProACT implantation. In addition, the study will evaluate whether treatment with
ProACT affects clinical outcomes after... expand
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies. Type: Interventional Start Date: Feb 2019 |
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory...
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in
treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly
diagnosed, has come back, or does not respond to treatment. Immunotherapy with monoclonal
antibodies, such as inotuzumab ozogamicin... expand
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Type: Interventional Start Date: May 2019 |
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Leland Metheny
Acute Lymphocytic Leukemia
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of
this research study is to see what doses post-transplant inotuzumab ozogamicin can safely
be given to subjects without having too many side effects.
The Phase II portion of this study is to see what side effects... expand
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study. Type: Interventional Start Date: Jul 2017 |
MEASuRE: Metreleptin Effectiveness And Safety Registry
Aegerion Pharmaceuticals, Inc.
Generalised Lipodystrophy
Partial Lipodystrophy
The study is a post-authorization, prospective, voluntary registry of patients treated
with commercial metreleptin including, but not limited to, patients in the US and EEA. expand
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA. Type: Observational [Patient Registry] Start Date: Oct 2016 |
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer...
ECOG-ACRIN Cancer Research Group
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
This study examines the impact of social and genetic factors on outcomes in adolescent
and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to
both older adult and childhood cancer patients, AYAs with cancer experience different
diagnoses and specific biological, clinical,... expand
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors. Type: Observational Start Date: Oct 2023 |
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Recurrent Ovarian High Grade Serous Adenocarcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given
together with olaparib in treating patients with ovarian cancer that responds at first to
treatment with drugs that contain the metal platinum but then comes back within a certain
period (recurrent platinum-resistant).... expand
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer. Type: Interventional Start Date: Jul 2021 |
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small...
SWOG Cancer Research Network
Lung Adenocarcinoma
Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating
non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and
has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may
cause the cancer to grow. AMG 510, a targeted... expand
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells. Type: Interventional Start Date: Apr 2021 |
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Mario Castro, MD, MPH
Asthma
COPD
Interstitial Lung Disease
Cystic Fibrosis
Pulmonary Hypertension
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized
(HP) 129Xe gas MRI for regional assessment of pulmonary function. expand
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function. Type: Interventional Start Date: Nov 2020 |
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
GT Medical Technologies, Inc.
Brain Tumor, Recurrent
Brain Tumor
Brain Tumor, Primary
Brain Tumor - Metastatic
Brain Tumor, Adult: Glioblastoma
The objectives of this registry study are to evaluate real-world clinical outcomes and
patient reported outcomes that measure the effectiveness and safety of STaRT. expand
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT. Type: Observational [Patient Registry] Start Date: Sep 2020 |
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer...
National Cancer Institute (NCI)
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
This phase II trial studies how well cabozantinib works in combination with nivolumab and
ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from
where it first started (primary site) to other places in the body. Cabozantinib may stop
the growth of tumor cells by blocking... expand
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone. Type: Interventional Start Date: May 2019 |
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative...
ECOG-ACRIN Cancer Research Group
CD20 Positive
Mantle Cell Lymphoma
This randomized phase III trial studies rituximab after stem cell transplant and to see
how well it works compared with rituximab alone in treating patients with in minimal
residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal
antibodies, such as rituximab, may interfere... expand
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma. Type: Interventional Start Date: Mar 2018 |
Early PKD Observational Cohort Study
University of Kansas Medical Center
Polycystic Kidney Disease
This observational study will collect blood and urine and clinical information from
individuals with early-stages of polycystic kidney disease (PKD), their unaffected
siblings and normal volunteers to create a biobank, also called a biorepository. The
long-term goal is to develop new knowledge on... expand
This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being developed and tested. Type: Observational [Patient Registry] Start Date: Apr 2016 |
Quantitative Pulmonary Imaging Registry & Biorepository
University of Kansas Medical Center
Pulmonary Disease
The goal of this project is to establish a registry and biorepository of images and
biological samples from subjects undergoing novel pulmonary imaging methods to be used
for future research aimed toward identifying clinical applications of imaging methods and
toward understanding the physiological... expand
The goal of this project is to establish a registry and biorepository of images and biological samples from subjects undergoing novel pulmonary imaging methods to be used for future research aimed toward identifying clinical applications of imaging methods and toward understanding the physiological significance of imaging biomarkers. This registry and biorepository will accelerate the development of these imaging techniques and may lead toward future clinical adoption of quantitative pulmonary imaging. Type: Observational [Patient Registry] Start Date: May 2022 |
Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension
University of Kansas Medical Center
Pulmonary Arterial Hypertension
In this study, hyperpolarized 129Xe MRI will be used to evaluate treatment efficacy in
patients with pulmonary arterial hypertension (PAH). Participants will be imaged at 4
timepoints (baseline, 6 weeks post-therapy initiation, 12 weeks, and 18 weeks). Images
will be analyzed to develop new biomarkers... expand
In this study, hyperpolarized 129Xe MRI will be used to evaluate treatment efficacy in patients with pulmonary arterial hypertension (PAH). Participants will be imaged at 4 timepoints (baseline, 6 weeks post-therapy initiation, 12 weeks, and 18 weeks). Images will be analyzed to develop new biomarkers and to understand treatment effects. Type: Observational Start Date: Aug 2022 |
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent...
National Cancer Institute (NCI)
Pancreatic Acinar Cell Carcinoma
Pancreatic Adenosquamous Carcinoma
Pancreatic Squamous Cell Carcinoma
Resectable Pancreatic Acinar Cell Carcinoma
Resectable Pancreatic Adenocarcinoma
This phase II trial investigates how well the addition of olaparib following completion
of surgery and chemotherapy works in treating patients with pancreatic cancer that has
been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or
PALB2. Olaparib is an inhibitor of PARP,... expand
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Type: Interventional Start Date: Jun 2021 |
- Previous
- Next